Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, yet no effective therapeutics exist. This review provides an overview of the recent development of recombinant immunotoxins for the treatment of glypican-3 (GPC3) expressing HCC. GPC3 is a cell surface heparan sulfate proteoglycan that is overexpressed in HCC, but is absent from normal adult human tissues. Treatment of HCC with anti-GPC3 immunotoxins represents a new therapeutic option. Using phage display and hybridoma technologies, three high affinity antibodies (HN3, HS20 and YP7) have been generated against GPC3. Two of these antibodies (HN3 and HS20) have demonstrated the ability to inhibit Wnt/Yap signaling, leading to a reduction in liver cancer cell proliferation. By combining the HN3 antibody capable of inhibiting Wnt/Yap signaling with the protein synthesis inhibitory domain of the Pseudomonas exotoxin, a recombinant immunotoxin that exhibits a dual inhibitory mechanism was generated. This immunotoxin was found to be highly effective in the treatment of human HCCs in mouse xenograft models. Engineering of the toxin fragment to reduce the level of immunogenicity is currently being explored. The development of immunotoxins provides opportunities for novel liver cancer therapies.
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Bryan.Fleming@nih.gov.
Bryan D
BD
Fleming
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. homi@mail.nih.gov.
Mitchell
M
Ho
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D053673:Glypicans / Q000276:immunology*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy*
C105937:GPC3 protein, human; D053673:Glypicans; D000922:Immunotoxins
glypican-3 (GPC3); hepatocellular carcinoma; liver cancer; monoclonal antibodies; pseudomonas exotoxin; recombinant immunotoxin
Blood. 1994 Oct 15;84(8):2457-66
7522629
Int J Cancer. 2015 Mar 1;136(5):E359-86
25220842
Hepatology. 2014 Aug;60(2):576-87
24492943
J Clin Oncol. 1997 Oct;15(10):3266-74
9336364
J Pharmacol Exp Ther. 2011 Apr;337(1):155-61
21205925
Lancet. 2012 Mar 31;379(9822):1245-55
22353262
Cancer Manag Res. 2016 May 19;8:57-65
27274311
J Stem Cells Regen Med. 2006 Dec 26;1(1):31-6
24692859
Cancer Res. 1997 Nov 15;57(22):5179-84
9371521
Front Microbiol. 2015 Sep 15;6:963
26441897
Cancer Res. 2008 Mar 1;68(5):1451-61
18316609
Nat Commun. 2015 Mar 11;6:6536
25758784
Cancer. 2014 Nov 1;120(21):3311-9
24989332
Immunol Rev. 2016 Mar;270(1):152-64
26864110
J Biol Chem. 1992 Dec 15;267(35):25396-401
1460035
N Engl J Med. 2001 Jul 26;345(4):241-7
11474661
Mol Cancer Ther. 2013 Jan;12(1):48-57
23136186
PLoS One. 2015 Sep 02;10(9):e0137664
26332121
Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
15508102
Cancer Res. 2005 Jul 15;65(14):6245-54
16024626
Infect Immun. 1992 Feb;60(2):497-502
1730481
Oncoimmunology. 2015 Feb 03;4(1):e985940
25949870
Breast Care (Basel). 2016 Apr;11(2):108-15
27239172
J Biomed Sci. 2016 Jul 20;23 (1):54
27439918
Clin Cancer Res. 2009 Aug 15;15(16):5274-9
19671873
Cancer Med. 2016 Jul;5(7):1454-63
27075560
Blood. 2009 Apr 16;113(16):3792-800
18988862
J Mol Biol. 2001 Dec 7;314(4):823-37
11734000
World J Hepatol. 2014 Oct 27;6(10):716-37
25349643
J Clin Oncol. 2012 May 20;30(15):1822-8
22355053
Biotechnol Lett. 2016 Oct;38(10 ):1655-64
27334710
Lancet Oncol. 2015 Jul;16(7):859-70
26095784
J Cell Sci. 1999 Feb;112 ( Pt 4):467-75
9914159
World J Gastroenterol. 2012 Nov 14;18(42):6005-17
23155330
Biol Pharm Bull. 2015;38(7):986-91
26133708
Clin Cancer Res. 2013 Sep 1;19(17):4717-27
23857604
Biochem J. 1995 Apr 1;307 ( Pt 1):29-37
7717988
Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213
17324579
Drugs. 2009;69(2):223-40
19228077
Clin Cancer Res. 2007 Sep 1;13(17):5144-9
17785569
Int J Immunopharmacol. 1991;13(2-3):305-15
2071302
J Biol Chem. 1993 Oct 15;268(29):21791-9
8408034
Blood. 1999 Oct 1;94(7):2217-24
10498591
Acta Pharmacol Sin. 2010 Sep;31(9):1198-207
20694021
Toxins (Basel). 2011 Jun;3(6):697-720
22069735
Clin Cancer Res. 2007 Feb 15;13(4):1133-9
17317821
FEBS J. 2011 Dec;278(23):4683-700
21585657
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
World J Gastroenterol. 2015 May 14;21(18):5445-53
25987766
J Exp Clin Cancer Res. 2011 Jul 07;30:67
21733192
J Bacteriol. 1987 Nov;169(11):4967-71
2889718
Toxins (Basel). 2016 Jun 21;8(6):null
27338475
Jpn J Clin Oncol. 2016 Mar;46(3):191-203
26819277
Curr Top Microbiol Immunol. 2005;300:149-68
16573240
Radiology. 2015 Dec;277(3):903-12
26131911
Cancer Lett. 2016 Jan 1;370(1):153-64
26499806
Immunity. 2000 Jul;13(1):117-27
10933400
Gastroenterology. 2009 Mar;136(3):1012-24
19150350
Mediators Inflamm. 2015 ;2015 :460264
25960617
Leukemia. 1995 Mar;9(3):382-90
7885036
Clin Cancer Res. 2011 Oct 15;17(20):6398-405
22003067
Ther Deliv. 2011 Jun;2(6):769-91
22822508
J Immunol Res. 2016;2016:5474602
27298832
Planta Med. 2014 Jul;80(11):896-901
25029173
Autoimmun Rev. 2011 Jun;10(8):469-73
21333759
Ann Surg Oncol. 2014 Apr;21(4):1314-22
24370904
Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1083-91
23471984
Blood. 1997 Sep 15;90(6):2188-95
9310469
N Engl J Med. 2015 Sep 24;373(13):1207-19
26308596
MAbs. 2012 Sep-Oct;4(5):592-9
22820551
Sci Transl Med. 2013 Oct 23;5(208):208ra147
24154601
J Hematol Oncol. 2016 Jun 30;9(1):51
27363983
Lancet Oncol. 2009 Jan;10(1):25-34
19095497
J Biol Chem. 1993 Aug 25;268(24):18195-9
8349695
Gastroenterol Hepatol (N Y). 2011 Jan;7(1):16-24
21346848
Hepatol Res. 2013 Feb;43(2):147-54
23145926
Genes Cancer. 2015 Mar;6(3-4):84-105
26000093
Clin Genitourin Cancer. 2016 Aug;14(4):277-83
26899142
Structure. 2011 Aug 10;19(8):1097-107
21827946
Curr Oncol Rep. 2014 Feb;16(2):365
24445497
World J Gastroenterol. 2016 Jan 7;22(1):275-83
26755876
Haematologica. 2015 Jun;100(6):794-800
25795722
Crit Rev Oncol Hematol. 2016 Aug;104:65-70
27279289
Mol Cancer Ther. 2015 Dec;14 (12 ):2789-96
26443804
Oncoimmunology. 2013 Oct 1;2(10):e26333
24251081
Toxins (Basel). 2014 Feb 28;6(3):869-91
24590384
Oncotarget. 2016 Jul 13;:null
27419635
Int J Cancer. 1995 Jul 28;62(3):351-5
7628878
MAbs. 2016;8(2):197-204
26651519
Lancet Oncol. 2016 Jun;17(6):e254-62
27299281
J Control Release. 2016 May 28;230:88-94
27067364
Cancer Res. 1998 Mar 1;58(5):968-75
9500458
Gastroenterology. 2003 Jul;125(1):89-97
12851874
Biochemistry. 1997 Sep 16;36(37):11051-4
9333321
Gut. 2010 Jul;59(7):953-62
20442200
Target Oncol. 2016 Apr;11(2):247-53
26891967
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12 ):4586-91
16537393
Drugs. 1989 Jun;37(6):871-99
2503348
Proc Natl Acad Sci U S A. 1990 Jan;87(1):308-12
2104981